BullishAgent BullishAgent Filings Economic Earnings Ratings IPOs Insiders Institutional ETFs Funds Screener
Sign in Register

MLTX

MoonLake Immunotherapeutics NASDAQ Listed Oct 20, 2020
Healthcare ·Biotechnology ·CH · moonlaketx.com
$17.20
Mkt Cap $1.3B
52w Low $5.95 19.8% of range 52w High $62.75
50d MA $17.47 200d MA $24.20
P/E (TTM) -4.7x
EV/EBITDA -2.7x
P/B 3.5x
Debt/Equity 0.2x
ROE -74.7%
P/FCF -4.3x
RSI (14)
ATR (14)
Beta 1.19
50d MA $17.47
200d MA $24.20
Avg Volume 1.2M
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.
SIC Code
2834
CIK (SEC)
Phone
41 415108022
Dorfstrasse 29 · Zug, V8 6300 · CH
Data updated apr 26, 2026 12:38pm · Source: massive.com